Intellia Therapeutics, Inc. (NASDAQ:NTLA) Shares Bought by Jump Financial LLC

Jump Financial LLC lifted its stake in Intellia Therapeutics, Inc. (NASDAQ:NTLA - Free Report) by 94.2% during the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 362,637 shares of the company's stock after purchasing an additional 175,885 shares during the period. Jump Financial LLC owned 0.36% of Intellia Therapeutics worth $4,228,000 at the end of the most recent quarter.

A number of other institutional investors have also made changes to their positions in the stock. Franklin Resources Inc. boosted its holdings in Intellia Therapeutics by 10.3% during the third quarter. Franklin Resources Inc. now owns 16,405 shares of the company's stock worth $320,000 after buying an additional 1,538 shares during the last quarter. Allspring Global Investments Holdings LLC raised its position in shares of Intellia Therapeutics by 14.0% in the 4th quarter. Allspring Global Investments Holdings LLC now owns 12,863 shares of the company's stock valued at $157,000 after acquiring an additional 1,582 shares during the period. Arizona State Retirement System boosted its stake in Intellia Therapeutics by 6.1% during the 4th quarter. Arizona State Retirement System now owns 28,006 shares of the company's stock worth $327,000 after acquiring an additional 1,615 shares during the last quarter. E Fund Management Co. Ltd. grew its holdings in Intellia Therapeutics by 10.0% during the fourth quarter. E Fund Management Co. Ltd. now owns 18,053 shares of the company's stock valued at $210,000 after purchasing an additional 1,634 shares during the period. Finally, China Universal Asset Management Co. Ltd. increased its stake in Intellia Therapeutics by 10.5% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 21,596 shares of the company's stock valued at $252,000 after purchasing an additional 2,059 shares in the last quarter. 88.77% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several brokerages have recently issued reports on NTLA. HC Wainwright began coverage on shares of Intellia Therapeutics in a report on Wednesday, March 5th. They issued a "buy" rating and a $30.00 price target for the company. JPMorgan Chase & Co. reaffirmed a "neutral" rating and set a $13.00 price objective (down from $45.00) on shares of Intellia Therapeutics in a research report on Friday, February 28th. BMO Capital Markets lowered their price target on shares of Intellia Therapeutics from $70.00 to $50.00 and set an "outperform" rating on the stock in a research note on Friday, January 10th. Wells Fargo & Company lowered their target price on shares of Intellia Therapeutics from $60.00 to $50.00 and set an "overweight" rating on the stock in a report on Friday, February 28th. Finally, Barclays reduced their target price on Intellia Therapeutics from $55.00 to $26.00 and set an "overweight" rating for the company in a research note on Friday, February 28th. Two investment analysts have rated the stock with a sell rating, six have issued a hold rating, twelve have given a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, Intellia Therapeutics has a consensus rating of "Moderate Buy" and a consensus target price of $36.68.

Intellia Therapeutics Stock Up 1.0 %

Shares of NASDAQ:NTLA traded up $0.08 during trading on Tuesday, hitting $8.00. The stock had a trading volume of 780,305 shares, compared to its average volume of 2,356,103. The stock has a 50-day simple moving average of $8.86 and a two-hundred day simple moving average of $12.04. The stock has a market capitalization of $828.34 million, a price-to-earnings ratio of -1.47 and a beta of 2.23. Intellia Therapeutics, Inc. has a 12-month low of $5.90 and a 12-month high of $28.18.

Intellia Therapeutics Profile

Intellia Therapeutics, Inc, a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease.